#USA #Spokane #Dermatopathology #Gestalt #Primaa

Gestalt and Primaa: A Transformative Partnership in Dermatopathology

In a groundbreaking collaboration, Gestalt, a frontrunner in digital pathology, and Primaa, a MedTech innovator specializing in AI-powered dermatopathology solutions, have joined forces to elevate skin cancer diagnosis. This partnership integrates Primaa's cutting-edge AI technology into Gestalt's renowned PathFlow platform, marking a significant evolution in pathology workflows.

Enhancing Diagnostic Precision

The integration aims to create seamless workflows for pathologists, enhancing both accuracy and patient safety. Gestalt's PathFlow platform has been notable for its versatility, already supporting various functions including primary diagnoses, resident training, and educational workflows. By adding Primaa's advanced AI algorithms to this mix, pathologists will now be equipped with sophisticated tools for identifying and quantifying tumor biomarkers in skin tissues.

Through this enhanced collaboration, pathologists can utilize AI-driven algorithms that automatically detect critical biomarkers associated with skin lesions. This feature is crucial in identifying various lesion types, such as melanoma, squamous cell carcinoma, and basal cell carcinoma, while also providing precise measurements of lesion sizes and margins. Notably, the system is designed to automatically detect perineural invasions and mitotic figures within melanoma, which are vital for accurate staging and treatment planning.

Additionally, the AI system prioritizes high-risk cases, allowing for immediate review, which is paramount for timely intervention. This forward-thinking approach aims not only to streamline workflows but also to ensure that pathologists can focus on what matters most — delivering high-quality patient care.

Quotes from the Leadership

Lisa-Jean Clifford, COO and Chief Strategy Officer of Gestalt, emphasizes the significant impact of this partnership, stating, "Integrating Primaa's AI technology into PathFlow underscores our commitment to providing pathologists with state-of-the-art tools. This collaboration represents a pivotal advancement toward optimizing workflow efficiency and improving patient care concerning skin cancer."

Fanny Sockeel, CEO of Primaa, echoed this sentiment: "Our partnership with Gestalt marks a substantial step in integrating AI seamlessly into the daily functions of pathologists. We aim to empower these medical professionals with advanced technology that promotes quicker, more accurate diagnoses, ultimately leading to better patient outcomes."

What to Expect

Medical professionals and stakeholders interested in this innovative collaboration can learn more about the integration and its potential benefits by visiting Gestalt at booth #934 and Primaa at booth #820 during the USCAP conference slated for March 23-26, 2025. Here, attendees can explore how this collaboration is set to shape the future of dermatopathology.

About Gestalt

Gestalt Diagnostics is committed to transforming pathology with a configurable, intelligent, vendor-neutral, and AI-driven digital workflow. Its PathFlow solution is designed to provide interoperability that enables pathologists to diagnose diseases faster and more effectively. The platform includes professional, educational, and research modules, all aimed at meeting the diverse digital needs of healthcare facilities. With a focus on reducing repetitive tasks, Gestalt allows pathologists to dedicate more time to their essential roles in patient diagnosis.

For more information, visit Gestalt Diagnostics and follow them on LinkedIn at @Gestalt.

About Primaa

Founded in 2018, Primaa stands at the forefront of transforming cancer diagnostics through AI. By harnessing sophisticated image analysis and deep learning technologies, Primaa enhances the accuracy and efficiency of biomarker detection for major cancers. Their mission centers around empowering pathologists with automated and precise insights, which drives more personalized treatment options and improves overall patient outcomes. Visit Primaa for updates and details on their solutions.